[1]Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[2]Moyer MT,Gaffney RR.Pancreatic adenocarcinoma[J].N Engl J Med,2014,371(22):2139-2141.
[3]Von Hoff DD,Ervin T,Arena FP,et al.Increased survival in pancreatic cancer with nabpaclitaxel plus gemcitabine[J].N Engl J Med,2013,369(18):1691-1703.
[4]Evans A,Costello E.The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion [J].Front Physiol,2012,3(270):1-7.
[5]Yao S,Zhu Y,Chen L.Advances in targeting cell surface signaling molecules for immune modulation[J].Nat Rev Drug Discov,2013,12(2):130-146.
[6]Yumu Ito,Shunsuke Kondo,Kohei Tada,et al.Clinical development of immune checkpoint inhibitors [J].Biomed Res Int,2015,2015:12.
[7]Royal RE,Levy C,Turner K,et al.Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma [J].J Immunother,2010,33(8):828-833.
[8]Nivolumab Borghaei H,Paz-Ares L,Horn L,et al.Nivolumab versus docetaxel in advanced nonsquamous non-small cell lung cancer [J].N Engl J Med,2015,373(17):1627-1639.
[9]Robert C,Schachter J,Long GV,et al.Pembrolizumab versus ipilimumab in advanced melanoma [J].N Engl J Med,2015,372(26):2521-2532.
[10]Brahmer JR,Tykodi SS,Chow LQ,et al.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer [J].N Engl J Med,2012,366(26):2455-2465.
[11]Leventakos K,Mansfield AS.Advances in the treatment of non-small cell lung cancer:Focus on nivolumab,pembrolizumab,and atezolizumab [J].Bio Drugs,2016,30(5):397-405.
[12]Hardacre JM,Mulcahy M,Small W,et al.Addition of algenpentucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer:a phase 2 study [J].J Gastrointest Surg,2013,17(1):94-100.
[13]Lutz E,Yeo CJ,Lillemoe KD.A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma.A Phase II trial of safety,efficacy,and immune activation [J].Ann Surg,2011,253(2):328-335.
[14]T Le,Andrea Wang-Gillam,Vincent Picozzi.Safety and survival with GVAX pancreas prime and listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer dung [J].J Clin Oncol,2015,33(12):1325-1333.
[15]Ruden M,Puri N.Novel anticancer therapeutics targeting telomerase [J].Cancer Treat Rev,2013,39(5):444-456.
[16]Lucia Picariello,Cecilia Grappone,Simone Polvani,et al.Telomerase activity:An attractive target for cancer therapeutics[J].World J Pharmacol,2014,3(4):86-96.
[17]Bernhardt SL,Gjertsen MK,Trachsel S,et al.Telomerase peptide vaccination of patients with non-resectable pancreatic cancer:a dose escalation phase I/II study [J].Br J Cancer,2006,95(11):1474-1482.
[18]Middleton G,Silcocks P,Cox T,et al.Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac):an open-label,randomized,phase 3 trial [J].Lancet Oncol,2014,15(8):829-840.
[19]Zhang C,Hu B,Xiao L,et al.Pseudotying lentiviral vectors with lympgocytic choriomening it is virus glycoproteins for transduction of dendritic cells and in vivo immunization[J].Human Gene Therapy Methods,2014,25(6):328-338.
[20]Kimura Y,Tsukada J,Tomoda T,et al.Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma [J].Pancreas,2012,41(2):195-205.
[21]Ramos CA,Dotti G.Chimeric antigen receptor(CAR)-engineered lymphocytes for cancer therapy[J].Expert Opin Biol Ther,2011,11(7):855-873.
[22]Chang K,Pastan I.Molecular cloning of mesothelin,a differentiation antigen present on mesothelium,mesotheliomas,and ovarian cancers[J].Proc Natl Acad Sci USA,1996,93(1):136-140.
[23]Beatty GL,Haas AR,Maus MV,et al.Mesothelin-specific chimeric antigen receptor mRNA engineered T cells induce anti-tumor activity in solid malignancies.Cancer Immunol Res,2014,2(2):112-120.
[24]Porter DL,Levine BL,Kalos M,et al.Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia[J].N Engl J Med,2011,365(8):725-733.
[25] Maus MV,Haas AR,Beatty GL,et al.T cells expressing chimeric antigen receptors can cause anaphylaxis in humans[J].Cancer Immunol Res,2013,1(1):26-31.
[26]Gold DV,Modrak DE,Schutsky K,et al.Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft[J].Int J Can,2004,109(4):618-626.
[27]Ocean AJ,Pennington KL,Guarino MJ,et al.Fractionated radio immunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer:a phase 1 trial[J].Cancer,2012,118(22):5487-5506.
[28]Nedaeinia R,Avan A,Manian M,et al.EGFR as a potential target for treatment of pancreatic cancer:dilemma and controversies[J].Curr Drug Targets,2014,15(14):1298-1301.
[29]Philip PA,Benedetti J,Corless CL,et al.Phase III study in comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma:southwest oncology group-directed intergroup trial S0205[J].J Clin Oncol,2010,28(22):3605-3610.
[30]Saxby AJ,Nielsen A,Scarlett CJ,et al.Assessment of HER-2 status in pancreatic adenocarcinoma:correlation of immunohistochemistry,quantitative realtime RT-PCR,and FISH with aneuploidy and survival[J].Am J Surg Pathol,2005,29(9):1125-1134.
[31]Pratesi G,Petrangolini G,Tortoreto M,et al.Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu[J].J Immunother,2008,31(6):537-544.
[32]Assenat E,Azria D,Mollevi C,et al.Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure:results of the "THERAPY" phase 1-2 trial[J].Oncotarget,2015,6(14):12796-12808.
[33]Kindler HL,Niedzwiecki D,Hollis D,et al.Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer:phase III trial of the cancer and leukemia group B (CALGB 80303) [J].J Clin Oncol,2010,28(22):3617-3622.
[34]Bellone G,Smirne C,Mauri FA,et al.Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens:implications for survival[J].Cancer Immunol Immunother,2006,55(6):684-698.
[35]Chard LS,Lemoine NR,Wang Y.New role of Interleukin-10 in enhancing antitumor efficacy of oncolytic vaccinia virus for the treatment of pancreatic cancer[J].Oncoimmunology,2015,4(9):e1038689.
[36]Wu HH,Hwang-Verslues WW,Lee WH,et al.Targeting IL-17B-IL-17RB signaling with an anti-IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines[J].J Exp Med,2015,212(3):333-349.
[37]Le DT,Lutz E,Uram JN,et al.Evaluation of Ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer[J].J Immunother,2013,36(7):382-389.
[38]Rafael Winograd,Katelyn T Byrne,Rebecca A Evans,et al.Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma[J].Cancer Immunol Res,2015,3(4):399-411.